Stockreport

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vir Biotechnology, Inc.  (VIR) 
PDF – Successful closing of exclusive worldwide licensing agreement with Sanofi for three potential best-in-class clinical-stage dual-masked T-cell engagers with initial cli [Read more]